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Binding of Shiga Toxin 2e to Porcine Erythrocytes In Vivo and In Vitro
Abstract
Shiga toxin 2e (Stx2e), produced by host-adapted Shiga toxin-producingEscherichia coli (STEC) strains,
causes edema disease in weaned pigs. Edema disease is manifested as vascular necrosis, edema, neurologic
signs, and death. In this study we sought to determine the correlation between the presence of Stx2e in the
blood of STEC-inoculated pigs and the disease outcome. Eleven of 15 (73%) pigs with clinical and 5 of 35
(14%) pigs with subclinical edema disease had detectable levels of Stx2e in the red-blood-cell (RBC) fraction
of their blood but not in serum or plasma. The presence of Stx2e in the RBC fraction was strongly associated
with the development of clinical disease (relative risk, 5.8; P < 0.0001). Subclinical pigs with Stx2e in their
blood developed more-extensive vascular lesions than pigs without detectable Stx2e in their blood (average
proportions of necrotic arterioles, 63 and 27.5%, respectively; P = 0.001). Variations in RBC-bound Stx2e
levels could in part reflect variations in the binding capacity of RBCs. As an initial step toward addressing this
possibility, assays were conducted to determine if pigs vary in the Stx2e binding capacity of their RBCs. An in
vitro study of noninoculated pigs demonstrated two phenotypes based on the capacity of the RBCs to bind
Stx2e. While RBCs from most of the pigs consistently bound high levels of Stx2e (high-binding phenotype),
consistently low Stx2e binding was detected in RBCs from a few pigs (low-binding phenotype). The low- and
high-binding phenotypes of individual pigs remained consistent throughout repeated samplings over 2
months.
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Shiga toxin 2e (Stx2e), produced by host-adapted Shiga toxin-producing Escherichia coli (STEC) strains,
causes edema disease in weaned pigs. Edema disease is manifested as vascular necrosis, edema, neurologic
signs, and death. In this study we sought to determine the correlation between the presence of Stx2e in the
blood of STEC-inoculated pigs and the disease outcome. Eleven of 15 (73%) pigs with clinical and 5 of 35 (14%)
pigs with subclinical edema disease had detectable levels of Stx2e in the red-blood-cell (RBC) fraction of their
blood but not in serum or plasma. The presence of Stx2e in the RBC fraction was strongly associated with the
development of clinical disease (relative risk, 5.8; P < 0.0001). Subclinical pigs with Stx2e in their blood
developed more-extensive vascular lesions than pigs without detectable Stx2e in their blood (average propor-
tions of necrotic arterioles, 63 and 27.5%, respectively; P 0.001). Variations in RBC-bound Stx2e levels could
in part reflect variations in the binding capacity of RBCs. As an initial step toward addressing this possibility,
assays were conducted to determine if pigs vary in the Stx2e binding capacity of their RBCs. An in vitro study
of noninoculated pigs demonstrated two phenotypes based on the capacity of the RBCs to bind Stx2e. While
RBCs from most of the pigs consistently bound high levels of Stx2e (high-binding phenotype), consistently low
Stx2e binding was detected in RBCs from a few pigs (low-binding phenotype). The low- and high-binding
phenotypes of individual pigs remained consistent throughout repeated samplings over 2 months.
Shiga toxins (Stx) are bacterial exotoxins that inhibit protein
synthesis in mammalian cells. Stx are produced by many strains
of Escherichia coli, by some strains of Shigella, and less fre-
quently by other bacteria (9, 22, 25). E. coli strains can produce
Stx1 and/or Stx2 or Stx2 variants (22, 23). Stx are composed of
an enzymatic A subunit and five receptor binding B subunits.
After binding of the B subunits to the glycolipid receptor
(globotriaosyl ceramide [Gb3] or globotetraosyl ceramide
[Gb4]) on mammalian cells, the A subunit is activated and
cleaves a specific adenine residue on the 28S rRNA, thus
inhibiting protein synthesis.
Edema disease is a disease of young pigs caused by host-
adapted Escherichia coli that produces a variant of Stx2, called
Stx2e (3). Porcine Stx-producing E. coli (STEC) strains colo-
nize the lower small intestine by F18 fimbria-mediated adhe-
sion and produce Stx2e locally (3, 8, 12). A portion of intralu-
minal toxin is absorbed into the blood and carried to the
sensitive tissues (intestine and brain), causing vascular necro-
sis, edema, neurologic signs, and death (16, 17). The level of
intraintestinal toxin produced is different for different individ-
ual pigs, and this variation is reflected in their fecal toxin titers
(8). Although pigs with high fecal toxin titers are more likely to
succumb to clinical disease (neurologic signs, edema, or death)
than are those with low toxin titers, fecal toxin titers are not
predictive of the disease outcome for individual pigs. Some
pigs develop high fecal Stx2e titers while remaining clinically
normal (8). Others, with comparatively low fecal Stx2e titers,
develop clinical signs and die. Some STEC-inoculated pigs
with clinical edema disease have detectable Stx2e in the red-
blood-cell (RBC) fraction of their blood (but not in serum) (8).
In experimental trials only 30% of STEC-inoculated pigs de-
veloped clinical signs (5, 8). Additional parameters that are
thought to influence the outcome of infection (besides the
amount of toxin produced within the intestine) are intestinal
permeability, the amount of Stx2e transported into the blood,
and the portion of Stx2e in blood that is actually available to
susceptible endothelial cells (6, 8, 37). Porcine RBCs are rich
in surface Gb4, a glycolipid receptor for Stx2e (6). In vitro
binding experiments suggest that most Stx2e activity localizes
in the RBC fraction of porcine whole-blood samples, with little
or no verotoxicity detected in the plasma fraction (8). Stx2e
apparently also binds to RBCs in vivo when injected intrave-
nously in pigs (6). Binding of Stx2e to RBCs may be a means
for delivery of the toxin to sensitive tissues (6, 8). Alternatively,
it is conceivable that RBC binding may temporarily protect
sensitive tissues from exposure to Stx by rendering the toxin
less available to endothelial cells (32). Binding of toxin to
porcine RBCs in vivo apparently does not protect pigs against
clinical edema disease, but it may delay toxin transfer into
tissues (6, 8).
In humans STEC causes a lethal systemic vascular disease,
hemolytic-uremic syndrome (HUS) (15, 31). The STEC strains
implicated in HUS often, but not always, belong to serogroup
O157:H7, colonize the large intestine via intimin-mediated ad-
hesion, and produce Stx1 and/or Stx2 or its variants (22, 23).
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The pathogenesis of HUS is not completely understood. It is
assumed that Stx directly or indirectly damages glomerular
capillaries, causing endothelial cell necrosis and/or apoptosis,
fibrin deposition in capillaries, and microvascular thrombosis
along with thrombocytopenia and hemolytic anemia. Intesti-
nally produced Stx is apparently transported across the epithe-
lium and delivered to the target tissues (kidney, intestine, and
brain) through systemic circulation (1). Stx bind to human
RBCs, monocytes, and neutrophils in vitro without causing
morphological changes in these cells (4, 26, 34). Binding of Stx
to human RBCs in vitro varies among individuals depending
on their P blood group phenotype (4). RBCs with a P1 phe-
notype (determined by P1 antigen, a glycolipid with a terminal
sugar residue identical to that of Gb3) bind Stx more abun-
dantly than RBCs with a P2 phenotype. Taylor et al. have
proposed that RBCs of the P1 phenotype may act as a sink to
bind Stx in vivo, thus preventing or delaying toxin binding to
the sensitive endothelial cells in the target tissues (32). How-
ever, epidemiological data suggest that the P1 phenotype does
not protect STEC-infected patients from HUS (2, 13, 21, 24,
27).
The study reported here is composed of two parts: in vivo
experiments utilizing a previously described edema disease
model and in vitro experiments. The objectives of the in vivo
experiments were to determine (i) the incidence and duration
of Shiga toxemia in pigs experimentally inoculated with host-
adapted STEC and (ii) whether the levels of Stx2e bound to
RBCs in such pigs correlate with the severity of disease. In the
second, in vitro part of the study, we sought to determine
whether pigs, like humans, vary in the capacity of their RBCs
to bind Stx2e.
MATERIALS AND METHODS
Bacterial strains. Stx2e-producing E. coli S1191 is from a pig with edema
disease (18). This strain belongs to serogroup O139 and produces F18ab fim-
briae, hemolysin, and heat-stable enterotoxin B (STb). E. coli S1191 is resistant
to chloramphenicol. E. coli 123 is a nonpathogenic isolate from a healthy pig
(serogroup O143). Inocula were prepared as described elsewhere (29).
In vivo experiments. (i) Experimental design. The design used here for repro-
duction of edema disease in STEC-inoculated pigs was essentially that utilized
previously (5, 8, 20). All animal experiments were carried out in accordance with
the protocol approved by the Iowa State University Animal Care and Use
Committee. Fifty pigs (weaned at the age of 14 to 16 days) in a total of five
replicates were orally inoculated with 1010 CFU of STEC strain S1191. Fourteen
control pigs were inoculated with 1010 CFU of the nonpathogenic E. coli strain
123. Room temperature was maintained at 24 to 27°C, and heat lamps were
available. Pigs were fed an antibiotic-free diet, with a protein content of 21%,
ad libitum throughout the study (5). Pigs were inoculated 8 to 10 days after
weaning. STEC shedding status was assessed as previously described (8).
Throughout the experiments pigs were observed three times a day for signs of
edema disease (subcutaneous edema, neurologic impairment). Pigs that devel-
oped clinical signs of edema disease were designated clinical pigs. STEC-inocu-
lated pigs that remained free of clinical signs until the termination of the exper-
iments, 13 to 14 days postinoculation (p.i.), were designated subclinical pigs. Pigs
were euthanized with intravenous barbiturate. At necropsy, pigs were examined
for gross lesions indicative of edema disease or concurrent diseases.
(ii) Histopathology. Samples from two ileum sites (1 and 2 m proximal from
the ileocecal junction) and the brain stem (medulla oblongata) were collected in
10% neutral buffered formalin from all pigs at necropsy. Tissue samples were
embedded in paraffin, sectioned at 5 m, and processed for staining with hema-
toxylin and eosin. Slides were coded such that the pathologist was blinded to the
treatment of the pigs. Slides were examined microscopically for vascular lesions
(20). The extent of vascular lesions in subclinical pigs from four replicates (n 
25) was assessed by determining the percent necrotic arteriolar profiles per tissue
section. Results from all sites examined were averaged. Slides from all clinical
pigs and from the subclinical pigs from one replicate were evaluated qualita-
tively. For these pigs, a section was considered positive if two or more vascular
profiles were necrotic.
(iii) Vero cell assay for Stx2e in the feces and blood. Fecal samples from 14
control and 30 STEC-inoculated pigs were collected every other day from 2 to 10
or 3 to 11 days p.i. Fecal samples were stored at 4°C until they were processed
as described elsewhere (8).
Blood samples for the Stx2e assay were collected (in EDTA) from 50 STEC-
inoculated and 14 control pigs every other day from 2 to 10 or 3 to 11 days p.i.
Serum samples were also collected from some pigs 2 to 11 days p.i. Pigs that
developed clinical edema disease were bled upon the onset of clinical signs (if the
signs were mild) and/or prior to euthanasia. Although pigs were monitored three
times daily for clinical signs of edema disease, some STEC-inoculated pigs were
found dead without previously noted clinical disturbances.
Blood samples (in EDTA) were centrifuged at 1,500  g for 10 min, the buffy
coat layer was discarded, and the RBC and plasma fractions were collected.
Serum samples were centrifuged at 1,500  g for 10 min, and supernatants were
collected. RBC, plasma, and serum fractions were stored at 4°C for 1 to 4 days
before being assayed on Vero cells.
Assays of the blood fractions (RBC, plasma, and serum) and feces for Stx2e
were carried out on monolayers of Vero cells as described previously (10, 11).
Twofold dilutions of fecal supernatants and of plasma, serum, and RBC fractions
were made in Hanks’ balanced salt solution (HBSS) without Ca2, Mg2, or
phenol red. The toxin titer was expressed as the log2 of the reciprocal of the
highest dilution that caused the death of 50% of Vero cells. Some control pigs
had low titers (4 to 5) of nonspecific Vero cell toxicity (not neutralized by an
anti-Stx2e antibody) in their RBCs, plasma, and feces. Therefore, samples were
considered to be positive for Stx2e if the Vero cell titer was 6 and the sample
(or another sample of the same type from the same pig) was neutralized by a
bovine polyclonal antibody against Stx2e (36) but not by fetal calf serum. Sam-
ples were considered neutralized if the polyclonal antibody reduced the toxin
titer 4-fold (14).
In vitro analysis. (i) Fluorescence-activated cell sorter (FACS) analysis. Blood
samples were collected (in heparin) from 4 adult and 30 weaned pigs over a
period of 2 months at 1- to 3-week intervals. Samples from each adult pig were
collected on weeks 1, 2, 3, and 6. Samples from each weaned pig were collected
on weeks 1, 2, 4 (n  30), and 7 (n  8). Immediately after collection, blood
samples were centrifuged (at 1,100  g and 4°C for 6 min), and the plasma and
buffy coat were discarded. RBCs were washed in HBSS (without Ca2, Mg2, or
phenol red), and the centrifugation was repeated. The purity of such RBC
preparations obtained from three animals was assessed with a Coulter cell
counter. On average, the resultant cell pellet consisted of 99.2% RBCs, 0.04%
white blood cells (including 0.016% neutrophils), and 0.8% platelets (data not
shown). Processed RBC fractions were stored at 4°C until they were assayed
(within 1 week of sample collection).
Purified Stx2e (0.1 g/ml; Vero cell toxicity, 106 50% cytotoxic doses [CD50]/
ml) or semipurified Stx2e (Stx2e-SP) with a similar level of Vero cell toxicity was
used to inoculate RBC samples (28). Stx2e-SP was produced as described for
purified Stx2e except that chromatofocusing was not done (28). Ten microliters
of the packed RBC fraction from each pig was incubated with 100 l (105 Vero
cell CD50) of Stx2e (for adult pigs) or Stx2e-SP (for weaned pigs) at 37°C for 1 h.
Samples were then centrifuged (at 1,000 g for 6 min in a microcentrifuge), and
the supernatant was discarded. RBCs were suspended in FACS buffer (0.1%
[wt/vol] NaN3 and 1.0% [wt/vol] bovine serum albumin fraction V diluted in
HBSS) to a concentration of 107 to 108 cells/ml. Two samples of the RBC
suspension per pig, 50 l each (approximately 106 RBCs), were transferred to
FACS tubes (Fisher Scientific, Pittsburgh, Pa.). One sample was incubated with
10 l of primary bovine anti-Stx2e immunoglobulin G (IgG; 20 g/ml [36]) for 30
min at 4°C (test sample). The other sample was incubated with 10 l of bovine
control IgG (10 g/ml; Sigma-Aldrich, St. Louis, Mo.) under the same conditions
(control sample). After incubation, samples were washed twice with 2 ml of
FACS buffer. After the second wash, the supernatant was discarded and 10 l of
a fluorescein isothiocyanate-conjugated secondary rabbit anti-bovine IgG (heavy
and light chains, 730 g/ml; ICN, Costa Mesa, Calif.) was added to the RBC
fractions of test and control samples. These suspensions were then incubated for
30 min at 4°C. Samples were washed twice, and 400 l of FACS buffer was added
to the RBC fraction after the second wash. Samples were stored in the dark at
4°C for 24 h until analysis with a FACScan flow cytometer (Becton Dickinson,
San Jose, Calif.). The fluorescence intensity of fluorescein isothiocyanate was
measured with excitation at 488 nm and emission at 530 nm. Mean fluorescence
intensities (MFI) were expressed as geometric means. The MFI for the sample
from each pig was calculated by subtracting the MFI of the control sample from
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the MFI of the test sample. The MFI of control samples were similar to those of
RBCs alone (MFI, 4 to 7).
(ii) Saturation of RBCs with Stx2e. FACS analysis showed that pigs could be
grouped into two populations according to their Stx2e binding patterns: a pop-
ulation with a low-binding (LB) phenotype and one with a high-binding (HB)
phenotype. To test whether these two populations of pigs also differed in the
amount of biologically active Stx2e that would bind to the RBC fraction, RBC
suspensions in HBSS were incubated with saturating amounts of Stx2e (for adult
pigs) or Stx2e-SP (for weaned pigs), and the Vero cell toxicity of the supernatant
was then measured. Pigs with the LB phenotype were expected to have higher
toxin titers in the supernatant, since their RBCs could bind less toxin.
Stx2e (104 Vero cell CD50) was added to 200 l of the RBC pellet. HBSS was
then added to the RBC-Stx2e mixture to make a final 30% (vol/vol) suspension
of RBCs. RBC-Stx2e suspensions were incubated under the same conditions as
the samples prepared for FACS analysis (1 h at 37°C). After incubation, RBCs
were separated from the test supernatant by centrifugation at 1,000 g for 4 min
in the microcentrifuge. The RBC pellet was washed once with HBSS, and the
centrifugation was repeated. Twofold dilutions of washed RBCs and test super-
natants were made in HBSS prior to assay of these fractions on Vero cell
monolayers. Samples collected in two different weeks from 12 pigs (4 adult pigs
and 8 weaned pigs) were assayed.
Statistics. The Wilcoxon signed rank test was used to compare Stx2e titers in
the blood and feces of clinical and subclinical pigs on individual days and to
analyze the extent of vascular necrosis in pigs with and without Stx2e in the RBC
fraction. The Mann-Whitney test was used to compare Stx2e titers in the in vitro
RBC saturation assay. The prevalence of the LB phenotype was estimated using
a confidence interval based on the F distribution. Variation among samples was
expressed as the standard error of the mean (for parametric data). Results were
interpreted as significantly different if the P value was 0.05. Whenever numer-
ous tests of significance were done for a single data set, the significance level was
normalized by Bonferroni’s method.
RESULTS
In vivo experiments. (i) Clinical disease. None of the 14
control pigs developed edema disease. Fifteen of 50 STEC-
inoculated pigs developed clinical edema disease. The mean
incidence of clinical edema disease among the five replicates
was 30% (range, 0 to 60%). Clinical disease occurred 4 to 9
days p.i.
(ii) Stx2e titers in feces and blood. Fecal samples were
collected from 14 control and 30 STEC-inoculated pigs. Two of
four control pigs in one replicate developed diarrhea at days 9
to 11 p.i., and Stx2e was detected in the fecal samples from
these two pigs at this time. The E. coli colonies isolated from
these two pigs resembled those of the inoculum strain but were
not further characterized. We assumed that this represented a
late spontaneous STEC infection in the controls. Stx2e was not
detected in feces from any of the other control pigs. In con-
trast, it was detected in the feces from all infected pigs from
day 2 to day 11 p.i. The fecal Stx2e titers of clinical pigs were
not different from those of subclinical pigs (Fig. 1).
Stx2e was not detected in any of the blood fractions (RBC,
serum, or plasma) of control pigs sampled every other day (n
 14 pigs for the RBC fraction; n  5 pigs for the serum
fraction; n  4 pigs for the plasma fraction). Stx2e was de-
tected in the RBC fractions of 11 of 15 (73%) clinical and 5 of
35 (14%) subclinical STEC-inoculated pigs. Stx2e was not de-
tected in the serum or plasma fraction in any of the samples
collected every other day from 10 STEC-inoculated pigs. These
included five pigs that had Stx2e in their RBC fractions, two of
which were clinical pigs. The peak verocytotoxin titer in the
RBC fractions of the 15 clinical pigs was significantly higher
(median, 7; range, 3 to 10; P  0.0001) than that for the 35
subclinical pigs (median, 4; range, 1 to 10). Median daily vero-
cytotoxin titers in the RBC fractions of clinical and subclinical
pigs are shown in Fig. 1. Verocytotoxin titers in the RBC
fractions of clinical pigs were significantly higher than those for
subclinical pigs in samples collected at days 4 to 5 (P  0.001)
and 6 to 7 (P  0.05) p.i. The median verocytotoxin titer of
clinical pigs was also higher than that of subclinical pigs on
days 8 to 9 p.i., but the difference was not statistically signifi-
cant, probably because only three pigs remained in the clinical
group. Stx2e titers in the RBC fractions of clinical pigs tended
to peak at the time of clinical illness (Table 1). Stx2e was
detected during routine (every other day) blood collection in
the RBC fractions of three of six pigs that died suddenly. The
remaining nine pigs exhibited clinical signs of edema disease,
and Stx2e was detected in the blood of eight pigs at that time.
Stx2e was detected 1 to 3 days prior to the onset of clinical
signs in five of these eight pigs. The time between the detection
of clinical signs (subcutaneous edema, ataxia, head tilt, circling,
and recumbency) and death or euthanasia was less than 24 h.
Stx2e was detected in the RBC fraction as early as day 2 p.i.
(first sampling time) in both clinical and subclinical pigs (Fig.
2). Stx2e was detected in the RBC fraction in as many as three
or four consecutive samples collected every other day from
clinical and subclinical pigs, respectively. Examples of daily
blood Stx2e titers in selected clinical and subclinical pigs are
shown in Table 1.
(iii) Relative risk for detectable Stx2e titers in blood and
development of clinical disease. Pigs that had the highest fecal
Stx2e titers did not consistently have the highest levels of Stx2e
in the RBC fraction. Furthermore, neither fecal nor RBC
fraction toxin titers were predictive for the clinical outcome of
STEC infection for individual animals. However, high fecal
Stx2e levels were associated with an increased incidence of
Stx2e in the RBC fraction: 5 of 8 (63%) pigs with peak Stx2e
titers of 15 in feces had Stx2e in their RBC fractions, while
only 6 of 22 (27%) pigs with peak fecal Stx2e titers of 14 had
Stx2e in their RBC fractions. The relative risk for detectable
levels of Stx2e in the RBC fraction if the peak fecal Stx2e titer
was15 was 2.3 (95% confidence interval [95% CI], 1.0 to 5.5;
P  0.1). Four of eight (50%) pigs with peak fecal toxin titers
of 15 developed clinical disease (relative risk, 2.2; 95% CI,
0.8 to 0.2; P  0.2). The presence of Stx2e in the RBC fraction
was strongly associated with the development of clinical dis-
ease. Sixteen pigs had Stx2e in their RBC fractions, and 11 of
these 16 pigs (69%) developed clinical edema disease (relative
risk, 5.8; 95% CI, 2.2 to 15.5; P  0.0001).
(iv) Vascular lesions. Vascular necrosis was not detected in
any of the control pigs. Vascular necrosis (two or more ne-
crotic blood vessels per tissue) was detected in 14 of 15 clinical
pigs and 31 of 35 subclinical pigs. The extent of vascular ne-
crosis (quantity) was not assessed for clinical pigs. The extent
of vascular necrosis among subclinical pigs tended to be most
severe in those pigs that had Stx2e in their blood RBC frac-
tions (Fig. 3). Subclinical pigs with Stx2e in the blood (n  5)
had on average 63% of vascular profiles necrotic (median;
range, 44 to 66%). Subclinical pigs without detectable Stx2e in
the blood (n  20) had 27.5% of vascular profiles necrotic
(median; range, 0 to 65%). The difference between the two
groups was significant (P  0.001). While the vascular lesions
in subclinical pigs with Shiga toxemia were significantly more
extensive than those in pigs without Shiga toxemia, there was
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no direct correlation between the magnitude of Shiga toxemia
and the extent of vascular lesions (Fig. 3; Table 1).
In vitro analysis. (i) FACS. The MFI of RBC samples inoc-
ulated with Stx2e in vitro varied widely among pigs and among
samples (Fig. 4). However, a few pigs (1 of 4 adult pigs and 4
of 30 weaned pigs) had consistently low MFI (mean, 8.8  1.4)
at all sampling times. These pigs were designated LB pheno-
type pigs. All the other pigs had mean MFI of 18 and were
designated HB phenotype pigs. The mean MFI for the HB
group was 29.6  0.9. The low MFI of pigs with the LB
phenotype was due to the fact that a comparatively low pro-
portion of RBCs bound Stx2e. Although Stx2e bound to sig-
nificantly fewer RBCs in the LB pigs, the MFI per RBC that
bound Stx2e were similar for LB and HB phenotype pigs. For
example, 73% of gated RBCs from a pig with the HB pheno-
type bound Stx2e, while only 16% of gated RBCs from a pig
with the LB phenotype bound Stx2e. The MFI per individual
RBC that bound Stx2e was 76 for the HB phenotype pig and 79
for the LB phenotype pig.
The MFI for adult pigs with the HB phenotype were not
different from those for weaned pigs of the same phenotype,
indicating that there was not an apparent age effect on the
capacity of RBCs to bind Stx2e in vitro. HB and LB pheno-
types were found among both adult and weaned pigs, and the
particular binding phenotype of a pig was consistent through-
FIG. 1. Box plot depiction of daily fecal and blood verocytotoxin titers in pigs inoculated with Stx2e-producing E. coli. Fifty pigs were assayed
for verocytotoxin in the RBC fraction of their blood (35 subclinical pigs; 15 clinical pigs on days 2 to 3 p.i., 15 on days 4 to 5 p.i., 8 on days 6 to
7 p.i., and 3 on days 8 to 9 p.i.). Blood samples were collected from each pig every other day from day 2 to 10 or day 3 to 11 p.i. Thirty pigs were
assayed for fecal Stx2e on the same days (21 subclinical pigs; 9 clinical pigs on days 2 to 3 p.i., 8 on days 4 to 5 p.i., and 4 on days 6 to 7 p.i.).
Horizontal lines inside boxes represent medians. The lower and upper borders of the boxes represent the 25th and 75th percentiles, respectively.
Error bars indicate lowest and highest values (range). Some lines overlap.
TABLE 1. Extent of vascular necrosis and log2 verocytotoxin titers





Log2 verocytotoxin titerb on the
following days p.i.:
2–3 4–5 6–7 8–9 10–11
1227 Clinical ND 7 6*
1220 Subclinical 64 6 5 7 4 3
1126 Clinical ND 3 1 7 9*
1230 Subclinical 63 5 5 10 6 5
1132 Clinical ND 1 6 8 9*
1229 Subclinical 53 5 6 10 6 6
a Percent necrotic arteriolar profiles per tissue section. ND, not determined
for clinical pigs.
b Stx2e titers above the nonspecific range are boldfaced. An asterisk indicates
that the pig died or was euthanized.
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out the sampling period. The prevalence of pigs with the LB
phenotype was 15% (95% CI, 5 to 31%).
(ii) Saturation of RBCs with Stx2e. RBCs from Stx2e-inoc-
ulated pigs with LB and HB phenotypes were further charac-
terized by using the Vero cell assay. Stx2e titers of 9 were
found in the RBC fractions of the Stx2e-inoculated samples.
The median Stx2e titer in the test supernatant fractions of the
LB phenotype pigs was significantly higher than that for the
HB phenotype pigs (P  0.0051). The corresponding median
Stx2e titers in the test supernatant fractions from LB pheno-
type and HB phenotype pigs were 7.5 (range, 6.5 to 8.0) and 6
(range, 4.0 to 6.5), respectively.
DISCUSSION
In this study Stx2e was repeatedly detected in the RBC
fraction of the blood in most of the clinically ill pigs. This result
confirms previous findings and further supports the concept
that Stx is transported to the sensitive tissues via blood (8).
Stx2e was not detected in any serum and/or plasma samples of
STEC-inoculated pigs, including those that were collected
from clinical pigs with detectable Stx2e titers in the RBC frac-
tions of their blood, indicating that Stx2e is rapidly bound to
RBCs and/or leukocytes or endothelial cells. Stx2e detection in
the RBC fraction of blood was associated with a high relative
risk for the development of clinical disease. Presumably, all
clinical pigs had at least a brief period of Shiga toxemia, and
our intermittent sampling was unable to detect it in some.
Stx2e was detected in the blood as early as day 2 p.i., and Shiga
toxemia lasted for several days in some pigs. Toxin titers in
blood tended to be highest at the time of clinical illness. Pre-
vious experiments have shown that Stx2e binding to RBCs
appears to delay toxin transfer into tissues (6). However, since
most pigs with detectable Stx2e in the blood became terminally
ill, it appears that Stx2e binding to RBCs was transient and that
the toxin was transferred to endothelial cells. The appearance
of Stx2e in the blood only a few days after inoculation with
STEC suggests that early events in STEC pathogenesis are
critical to disease outcome. This conclusion is also supported
by the observation that systemic intervention with an anti-
Stx2e antibody within the first few days after inoculation with
STEC can prevent the development of clinical edema disease
(19).
We demonstrated that some subclinical pigs also had detect-
able levels of Stx2e in their RBC fractions. The levels of Stx2e
in the blood, as well as the duration of Shiga toxemia in these
five subclinical pigs, were comparable to those of clinical pigs.
This suggests that additional factors must play a role in deter-
mining the outcome of STEC infection in these pigs. One of
the factors that may influence the pathogenesis of STEC in-
fection is the rate of Stx transport across the intestinal mucosa
into the bloodstream. One bolus of Stx1 (100 ng/kg of body
weight) given intravenously to baboons causes lethal acute
renal failure; however, four divided doses of Stx1 (25 ng/kg 
FIG. 2. Log2 verocytotoxin titers in the RBC fractions of clinical (n  15) and selected subclinical (n  5) pigs inoculated with Stx2e-producing
E. coli. All five subclinical pigs had at least one blood sample positive for verocytotoxin. A sample was considered to be positive for Stx2e if the
Vero cell titer was 6 log2 units and the sample (or another sample of the same type from the same pig) was neutralized by a bovine polyclonal
antibody against Stx2e but was not neutralized by fetal calf serum. The line indicates the maximum nonspecific verocytotoxicity of blood.
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4) given at 12-h intervals do not result in clinical or histologic
features of HUS (30). Presumably, Stx2e is continuously trans-
ferred across the intestinal mucosa after pigs are infected with
STEC. Pigs that developed clinical signs of edema disease
tended to have significantly higher levels of Stx2e in the RBC
fraction of blood earlier (days 4 to 5 p.i.) than subclinical pigs
(Fig. 1 and 2), indicating that the rate of toxin transfer from the
intestinal lumen into the bloodstream may be higher in clinical
pigs than in subclinical pigs. For a few subclinical pigs, how-
ever, Shiga toxemia was nearly identical in magnitude, dura-
FIG. 3. Extent of vascular necrosis (percent necrotic arteriolar profiles per tissue section) in relation to peak verocytotoxin titer in subclinical
pigs inoculated with STEC (n  25). Samples were considered to be positive for Stx2e if the Vero cell titer was 6 log2 units and the sample (or
another sample of the same type from the same pig) was neutralized by a bovine polyclonal antibody against Stx2e but was not neutralized by fetal
calf serum. The line indicates the maximum nonspecific verocytotoxicity of blood.
FIG. 4. FACS analysis of Stx2e binding to porcine RBCs in vitro. Three to four samples per pig (collected over a period of 2 months at 1- to
3-week intervals) were analyzed and results were averaged. This analysis was performed for 5 pigs with the LB phenotype (MFI range, 5 to 12)
and 29 pigs with the HB phenotype (MFI range, 18 to 37). Bars, standard errors of the means.
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tion, and timing to that observed for clinical pigs (Table 1),
indicating that factors other than the rate of toxin transfer into
the blood play a role in these pigs. Alternatively, it is possible
that blood Stx2e titers do not reflect the total amount of toxin
absorbed into systemic circulation and that some portion of
toxin may bind directly to tissue receptors without prior bind-
ing to RBCs.
Subclinical pigs with Shiga toxemia had extensive vascular
lesions, indicating that the lack of clinical disease was not due
to the lack of vascular receptors for Stx2e. However, there was
no consistent direct correlation between the magnitude and/or
duration of Shiga toxemia and the extent of vascular lesions in
individual subclinical pigs. For example, pig 1229 had 53% of
blood vessels necrotic, and Stx2e titers in its blood were 6, 10,
6, and 6 log2 units on days 5 to 11 p.i. (Table 1). Pig 1230
attained similar levels of Stx2e but had a shorter duration of
Shiga toxemia, yet its vascular necrosis was more extensive,
affecting 63% of blood vessels. While it is possible that these
numbers are within the range of experimental variation, these
differences may reflect individual animal variability in suscep-
tibility to systemic Stx2e effects.
The first part of our study demonstrated that binding of in
vivo-produced Stx2e to RBCs was detectable in most (11 of 15)
clinical pigs and some (5 of 35) subclinical pigs. Therefore, we
hypothesized that pigs may differ in the capacity of their RBCs
to bind Stx2e when exposed to toxin in vitro. Two methods
were used to test this hypothesis: FACS analysis to demon-
strate binding and a Vero cell assay to measure the amount of
biologically active RBC-bound toxin. Processing of blood sam-
ples ensured that 99% of cells incubated with Stx2e were
RBCs. The results of FACS and Vero cell assays correlated
with one another and demonstrated that two binding pheno-
types exist in the pig population: pigs whose RBCs bind vari-
ably large amounts of Stx2e (HB phenotype) and pigs whose
RBCs consistently bind little Stx2e (LB phenotype). Toxin
bound to RBCs was biologically active, causing Vero cell
death, presumably because Gb4 receptors on Vero cells bound
Stx2e more avidly than receptors on RBCs, resulting in the
transfer of the toxin from RBCs to Vero cells. RBC suspen-
sions from LB phenotype pigs had significantly larger amounts
of biologically active Stx2e in the supernatants than RBC sus-
pensions from HB phenotype pigs.
Our in vitro findings indicated that pigs with the LB pheno-
type may be similar to humans with the rare P2 blood group,
who bind only comparatively small amounts of Stx to their
RBCs (4). Pig RBCs have been shown to be rich in Gb4, and
it is assumed that Stx2e binds to this receptor (6). LB pheno-
type pigs had a markedly reduced portion of RBCs that bound
Stx2e; however, the small proportion of RBCs that did bind
Stx2e in LB phenotype pigs bound toxin at the same level as
the RBCs in HB phenotype pigs. These findings suggest that
only a small proportion of RBCs in LB phenotype pigs express
Gb4 or another Stx2e binding receptor. The LB phenotype was
stable; pigs maintained it throughout the sampling period (2
months), indicating that this phenotype is not age dependent.
It is not known whether the LB phenotype is a risk factor for
the development of clinical edema disease. Reduced binding of
Stx2e to the RBCs could theoretically result in increased bind-
ing of absorbed Stx2e directly to the toxin receptors on the
endothelial cells, causing rapid, simultaneous saturation of re-
ceptors and leading to clinical edema disease. A similar hy-
pothesis has been proposed for P blood types in human pa-
tients (32). However, a recent study refuted this possibility by
showing that the P1 blood group was equally represented in
healthy controls and E. coli O157:H7-infected children regard-
less of whether patients had uncomplicated illness or HUS
(13), confirming the findings of previous studies that failed to
associate P1 expression with diminished risk for the develop-
ment of HUS after infection with E. coli O157:H7 (2, 21, 24,
27).
Alternatively, the LB phenotype could be associated with
enhanced resistance against edema disease if reduced expres-
sion of Stx2e receptors on the RBCs in these pigs is reflected
in reduced tissue receptor expression generally. It would be
useful to determine if the binding phenotype of pigs affects
their susceptibility to disease. In a pilot study, 10 randomly
selected weaned pigs were inoculated with STEC S1191 as
described above, and their binding phenotypes were deter-
mined prior to and after inoculation (I. Matise, unpublished
data). All pigs had the HB phenotype, and this phenotype was
maintained throughout the study. One pig developed clinical
edema disease, indicating that pigs with the HB phenotype are
susceptible to clinical edema disease. Experiments to deter-
mine if clinical disease incidence varies in groups of pigs rep-
resenting each binding phenotype equally are warranted.
In humans, Stx also binds to blood neutrophils, monocytes,
and platelets in vitro (7, 26, 34). Stx has also been recently
demonstrated in the blood of STEC-infected human patients
(33, 35). Stx2 bound to neutrophils was detected 3 to 14 days
after the onset of hemorrhagic diarrhea, in some patients re-
peatedly, with 5 days between sampling times. In vivo binding
to other blood cells (platelets, RBCs, or lymphocytes) was not
observed; however, limited binding to monocytes was detected.
Neutrophil-bound Stx was detected both in acutely infected
patients with hemorrhagic diarrhea and HUS and in their
asymptomatic household members (33). Studies to determine
whether Stx2e binds to porcine white blood cells are needed.
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